<p>阿伯丁集团（Aberdeen Group plc）在最近向美国证券交易委员会（SEC）提交的 13F 表格中披露，在第四季度将其在 Structure Therapeutics Inc.（纳斯达克代码：GPCR - 免费报告）的持股减少了 54.9%。该公司在此期间出售了 322,000 股后，持有 264,869 股该公司的股票。截至其最近向 SEC 提交的文件，阿伯丁集团持有的 Structure Therapeutics 股份占 0.44%，价值 1,842.2 万美元。</p>
<p>获取 <strong>Structure Therapeutics</strong> 的提醒：</p>
<ul>
<li>三家公司在 GLP-1 药物竞争中处于前沿</li>
</ul>
<p>其他一些机构投资者也对 GPCR 的持仓进行了调整。E. Ohman J 或资产管理公司在第四季度以约 314,000 美元的价格购买了 Structure Therapeutics 的新头寸。Gilbert &amp; Cook Inc.在第四季度以约 395,000 美元的价格收购了 Structure Therapeutics 的新股份。摩根大通（JPMorgan Chase &amp; Co.）在第三季度将其在 Structure Therapeutics 的持股增加了 37.0%。摩根大通目前持有 58,148 股该公司的股票，价值 1,628,000 美元，此前在上个季度又购买了 15,706 股。Alyeska Investment Group L.P.在第三季度以约 6,856,000 美元的价格收购了 Structure Therapeutics 的新股份。最后，Paradigm Biocapital Advisors LP 在第三季度以约 10,440,000 美元的价格收购了 Structure Therapeutics 的新股份。目前 91.78% 的股票由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>几位分析师最近对 GPCR 股票发表了看法。杰富瑞金融集团（Jefferies Financial Group）在 12 月 11 日的报告中将 Structure Therapeutics 的目标价设定为 125.00 美元，并给予该股票 “买入” 评级。摩根大通在 1 月 22 日的报告中将 Structure Therapeutics 的目标价从 65.00 美元上调至 105.00 美元，并给予该股票 “增持” 评级。Leerink Partners 在 3 月 16 日的报告中重申了对 Structure Therapeutics 的 “跑赢大盘” 评级。威廉·布莱尔（William Blair）在 3 月 16 日的研究报告中重申了对 Structure Therapeutics 的 “跑赢大盘” 评级。最后，华尔街 Zen 在 3 月 28 日的研究报告中将 Structure Therapeutics 的评级从 “持有” 下调至 “卖出”。两位股票研究分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，Structure Therapeutics 的平均评级为 “适度买入”，共识目标价为 110.00 美元。</p>
<ul>
<li>罗氏能否在减肥市场挑战礼来和诺和诺德？</li>
</ul>
<p><strong>查看我们对 GPCR 的最新分析</strong></p>
<h2>Structure Therapeutics 股价下跌 3.2%</h2>
<p>GPCR 股票周二开盘价为 51.77 美元。Structure Therapeutics Inc.的赞助 ADR 在过去一年中的最低价为 13.22 美元，最高价为 94.90 美元。该公司的市值为 36.7 亿美元，市盈率为-65.53，贝塔值为-1.17。该公司的 50 日移动平均线为 63.91 美元，200 日移动平均线为 53.03 美元。</p>
<ul>
<li>诺和诺德的挫折不会持续：一款改变游戏规则的药物出现</li>
</ul>
<p>Structure Therapeutics（纳斯达克代码：GPCR - 获取免费报告）最后一次公布财报是在 2 月 26 日，报告显示该季度每股收益（EPS）为-0.49 美元，低于市场共识预期的-0.35 美元，差距为-0.14 美元。卖方分析师预测，Structure Therapeutics Inc.的赞助 ADR 在当前年度将发布-0.82 美元的每股收益。</p>
<h2>Structure Therapeutics 简介</h2>
<p>（免费报告）</p>
<p>Structure Therapeutics（纳斯达克代码：GPCR）是一家临床阶段的生物技术公司，专注于发现和开发针对 G 蛋白偶联受体（GPCRs）的口服小分子疗法。该公司利用结构生物学、计算化学和药物化学的进展，科学平台旨在优化结合相互作用和药代动力学特性，目标是提供创新的代谢和炎症疾病治疗方案。</p>
<p>该公司的产品管线包括多个处于临床前和临床开发不同阶段的项目。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Structure Therapeutics</li>
</ul>
<p><strong>想看看其他对 GPCR 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Structure Therapeutics Inc.（纳斯达克代码：GPCR - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Structure Therapeutics 吗？</h2>
<p>在考虑投资 Structure Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Structure Therapeutics 并不在名单上。</p>
<p>虽然 Structure Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

基因改革 ETF - ARK

标普全球医疗股指数 ETF - iShares

生物科技 ETF - VanEck Vectors

<p>阿伯丁集团（Aberdeen Group plc）在结构治疗公司（Structure Therapeutics Inc.）的赞助美国存托股票（NASDAQ: GPCR）中减少了 54.9% 的持股，在第四季度出售了 322,000 股，剩余持有 264,869 股，价值 1840 万美元。其他机构投资者也调整了在 GPCR 的持仓。分析师对该股票的评级不一，普遍目标价为 110.00 美元。GPCR 的股票开盘价为 51.77 美元，下跌 3.2%，市值为 36.7 亿美元。该公司专注于开发针对 G 蛋白偶联受体的疗法</p>

<p>Aberdeen Group plc cut its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 54.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 264,869 shares of the company's stock after selling 322,000 shares during the period. Aberdeen Group plc owned 0.44% of Structure Therapeutics worth $18,422,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>阿伯丁集团（Aberdeen Group plc）在最近向美国证券交易委员会（SEC）提交的 13F 表格中披露，在第四季度将其在 Structure Therapeutics Inc.（纳斯达克代码：GPCR - 免费报告）的持股减少了 54.9%。该公司在此期间出售了 322,000 股后，持有 264,869 股该公司的股票。截至其最近向 SEC 提交的文件，阿伯丁集团持有的 Structure Therapeutics 股份占 0.44%，价值 1,842.2 万美元。</p>
</div><p>Get <strong>Structure Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Structure Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Companies at the Forefront of the GLP-1 Pill Wars</li>
</ul>
<div class="lb-trans"><ul>
<li>三家公司在 GLP-1 药物竞争中处于前沿</li>
</ul>
</div><p>A number of other institutional investors have also made changes to their positions in GPCR. E. Ohman J or Asset Management AB bought a new position in Structure Therapeutics during the fourth quarter valued at about $314,000. Gilbert &amp; Cook Inc. acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $395,000. JPMorgan Chase &amp; Co. grew its holdings in shares of Structure Therapeutics by 37.0% during the 3rd quarter. JPMorgan Chase &amp; Co. now owns 58,148 shares of the company's stock worth $1,628,000 after purchasing an additional 15,706 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Structure Therapeutics during the 3rd quarter worth approximately $6,856,000. Finally, Paradigm Biocapital Advisors LP acquired a new stake in shares of Structure Therapeutics during the 3rd quarter worth approximately $10,440,000. 91.78% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者也对 GPCR 的持仓进行了调整。E. Ohman J 或资产管理公司在第四季度以约 314,000 美元的价格购买了 Structure Therapeutics 的新头寸。Gilbert &amp; Cook Inc.在第四季度以约 395,000 美元的价格收购了 Structure Therapeutics 的新股份。摩根大通（JPMorgan Chase &amp; Co.）在第三季度将其在 Structure Therapeutics 的持股增加了 37.0%。摩根大通目前持有 58,148 股该公司的股票，价值 1,628,000 美元，此前在上个季度又购买了 15,706 股。Alyeska Investment Group L.P.在第三季度以约 6,856,000 美元的价格收购了 Structure Therapeutics 的新股份。最后，Paradigm Biocapital Advisors LP 在第三季度以约 10,440,000 美元的价格收购了 Structure Therapeutics 的新股份。目前 91.78% 的股票由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have recently weighed in on GPCR shares. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the stock a &#34;buy&#34; rating in a report on Thursday, December 11th. JPMorgan Chase &amp; Co. lifted their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, January 22nd. Leerink Partners reissued an &#34;outperform&#34; rating on shares of Structure Therapeutics in a report on Monday, March 16th. William Blair reiterated an &#34;outperform&#34; rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Wall Street Zen lowered Structure Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, March 28th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Structure Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $110.00.</p>
<div class="lb-trans"><p>几位分析师最近对 GPCR 股票发表了看法。杰富瑞金融集团（Jefferies Financial Group）在 12 月 11 日的报告中将 Structure Therapeutics 的目标价设定为 125.00 美元，并给予该股票 “买入” 评级。摩根大通在 1 月 22 日的报告中将 Structure Therapeutics 的目标价从 65.00 美元上调至 105.00 美元，并给予该股票 “增持” 评级。Leerink Partners 在 3 月 16 日的报告中重申了对 Structure Therapeutics 的 “跑赢大盘” 评级。威廉·布莱尔（William Blair）在 3 月 16 日的研究报告中重申了对 Structure Therapeutics 的 “跑赢大盘” 评级。最后，华尔街 Zen 在 3 月 28 日的研究报告中将 Structure Therapeutics 的评级从 “持有” 下调至 “卖出”。两位股票研究分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，Structure Therapeutics 的平均评级为 “适度买入”，共识目标价为 110.00 美元。</p>
</div><ul>
<li>Can Roche Challenge Lilly and Novo in the Weight Loss Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>罗氏能否在减肥市场挑战礼来和诺和诺德？</li>
</ul>
</div><p><strong>View Our Latest Analysis on GPCR</strong></p>
<div class="lb-trans"><p><strong>查看我们对 GPCR 的最新分析</strong></p>
</div><h2>Structure Therapeutics Trading Down 3.2%</h2>
<div class="lb-trans"><h2>Structure Therapeutics 股价下跌 3.2%</h2>
</div><p>GPCR stock opened at $51.77 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $94.90. The firm has a market cap of $3.67 billion, a P/E ratio of -65.53 and a beta of -1.17. The business's 50 day moving average is $63.91 and its 200-day moving average is $53.03.</p>
<div class="lb-trans"><p>GPCR 股票周二开盘价为 51.77 美元。Structure Therapeutics Inc.的赞助 ADR 在过去一年中的最低价为 13.22 美元，最高价为 94.90 美元。该公司的市值为 36.7 亿美元，市盈率为-65.53，贝塔值为-1.17。该公司的 50 日移动平均线为 63.91 美元，200 日移动平均线为 53.03 美元。</p>
</div><ul>
<li>Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德的挫折不会持续：一款改变游戏规则的药物出现</li>
</ul>
</div><p>Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.</p>
<div class="lb-trans"><p>Structure Therapeutics（纳斯达克代码：GPCR - 获取免费报告）最后一次公布财报是在 2 月 26 日，报告显示该季度每股收益（EPS）为-0.49 美元，低于市场共识预期的-0.35 美元，差距为-0.14 美元。卖方分析师预测，Structure Therapeutics Inc.的赞助 ADR 在当前年度将发布-0.82 美元的每股收益。</p>
</div><h2>Structure Therapeutics Profile</h2>
<div class="lb-trans"><h2>Structure Therapeutics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.</p>
<div class="lb-trans"><p>Structure Therapeutics（纳斯达克代码：GPCR）是一家临床阶段的生物技术公司，专注于发现和开发针对 G 蛋白偶联受体（GPCRs）的口服小分子疗法。该公司利用结构生物学、计算化学和药物化学的进展，科学平台旨在优化结合相互作用和药代动力学特性，目标是提供创新的代谢和炎症疾病治疗方案。</p>
</div><p>The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于临床前和临床开发不同阶段的项目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Structure Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Structure Therapeutics</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GPCR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 GPCR 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Structure Therapeutics Inc.（纳斯达克代码：GPCR - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GPCR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Structure Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Structure Therapeutics 吗？</h2>
</div><p>Before you consider Structure Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Structure Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Structure Therapeutics 并不在名单上。</p>
</div><p>While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Structure Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Market Beat

标普生物技术 3 倍做多 - Direxion

Structure Therapeutics

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

医疗业 ETF - SPDR

美国制药 ETF - iShares

阿伯丁集团有限公司出售了 322,000 股 Structure Therapeutics Inc.的赞助美国存托凭证 $GPCR